WP
SRPT icon

Woodline Partners’s Sarepta Therapeutics SRPT Stock Holding History

Woodline Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,986
Closed -$5.71M – 1022
2024
Q4 		$5.71M Buy
+46,986
New +$5.76M 0.04% 459
2024
Q3 		– Sell
-20,381
Closed -$3.22M – 700
2024
Q2 		$3.22M Buy
+20,381
New +$2.62M 0.03% 379
2022
Q4 		– Sell
-26,475
Closed -$2.93M – 839
2022
Q3 		$2.93M Buy
+26,475
New +$2.67M 0.04% 416

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Woodline Partners's SRPT Position: Q1 2025 in Review

Woodline Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 46,986 shares — an estimated $5.71M sold.

Woodline Partners first reported a position in SRPT in Q3 2022 and held it in 3 quarters. The position peaked at $5.71M in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Woodline Partners reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Woodline Partners sold 46,986 Sarepta Therapeutics shares in Q1 2025, an estimated $5.71M.
  • Woodline Partners first reported a position in Sarepta Therapeutics in Q3 2022 and held it in 3 quarters.
  • Woodline Partners's Sarepta Therapeutics position peaked at $5.71M in Q4 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Woodline Partners's 13F filing for Q1 2025, filed 15 May 2025.